drugset / Trial / NCT02962167
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Phase 1
Completed
34 enrolled
Sabine Mueller, MD, PhD
Mayo Clinic · collabNo More Kids With Cancer · collabThe Matthew Larson Foundation for Pediatric Brain Tumors · collabVyriad, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor (ATRT).
Timeline
- Start
- 2017-02-22
- Primary completion
- 2023-05-10
- Completion
- 2023-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MV-NIS | Unknown | — | Other |